Southwest Early Clinical Trials Consortium
西南早期临床试验联盟
基本信息
- 批准号:9022449
- 负责人:
- 金额:$ 44.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-14 至 2020-02-28
- 项目状态:已结题
- 来源:
- 关键词:Advanced Malignant NeoplasmAdverse eventAuthorshipBiochemicalBioinformaticsBiotechnologyBloodClinicalClinical ResearchClinical TrialsClinical Trials NetworkColoradoComprehensive Cancer CenterCytotoxic ChemotherapyDataDevelopmentDoseDose-LimitingDrug KineticsEarly Therapeutic-Clinical Trials NetworkEnsureEvaluationExplosionFacultyGenomicsGenotypeGoalsHumanImageInstitutionInstitutional Review BoardsInvestigational TherapiesLaboratory StudyLeadLeadershipMalignant - descriptorMalignant NeoplasmsMaximum Tolerated DoseMentorsMolecularMolecular AbnormalityNew AgentsNormal tissue morphologyPathologicPathway interactionsPatient RightsPatientsPharmaceutical PreparationsPharmacodynamicsPhasePhase I Clinical TrialsPopulationPositioning AttributeProtocols documentationPublicationsQualifyingRefractoryReportingResearch DesignResearch PersonnelResourcesSafetyScheduleScienceSkinSpecimenTechnologyTestingTherapeutic Clinical TrialTissuesTumor TissueUniversitiesUniversity of Texas M D Anderson Cancer Centerbasebiobankcarcinogenesisclinical practiceclinically relevantdrug testingexperienceimaging modalitymeetingsneoplasticnovelnovel strategiesoncologypatient populationpharmacodynamic biomarkerphase 2 studyphase I trialprofiles in patientsprospectiveprotocol developmentresponsesafety studyskillstargeted agenttargeted treatmenttumor
项目摘要
DESCRIPTION (provided by applicant): Recent advances in science and biotechnology have led to an explosion of data from the plethora of rapidly developing high throughput analyses. While these advances have led to major improvements in the therapy of several refractory malignancies, most advanced cancers remain incurable. The Southwest Early Clinical Trials (SECT) Consortium consists of University of Texas MD Anderson Cancer Center and University of Colorado Comprehensive Cancer Center, and is strategically and geographically placed to lead, collaborate on and execute phase I clinical trials in the NCI Experimental Therapeutics-Clinical Trials Network in broad patient populations, including in several underserved regions. Specifically, we propose to: 1. Study, in an efficient and collaborative manner, the safety and clinical activity of new agents or hypothesis-driven novel combinations. 2. Molecularly profile patients (host tissues) and their malignancies to optimize selection of potentially relevant therapy for each patient, based on identified molecular aberrations, where appropriate. 3. Develop clinically relevant pharmacodynamic markers of response. 4. Mentor junior faculty, trainees, and research personnel, as applicable, in the leadership, conduct, analysis, and reporting of ET-CTN and other clinical trials. 5. Provide scientific and administrative leadership within ET-CTN, including active participation in project teams, research design and protocol development, authorship/co-authorship of Network group publications, and participation in scientific, administrative, or ad hoc committees, as well as participation in the NCI Central IRBs and attendance at ET-CTN and IDSC meetings. In addition to established proficiency in clinical trial accrual, pharmacokinetics, and pharmacodynamic assessment, the SECT Institutions have an unparalleled combination of resources that include access to large patient populations with extensively genotyped tumors, established biorepositories, state of the art clinical genomics capabilities, and expert bioinformatics. Led by three experienced principle investigators with complementary skills, the SECT consortium is poised to execute a new paradigm for early experimental therapeutic clinical trials, with the goals to validate the right pathways, target thee pathways with the right drugs, and test these drugs in the right patients.
RELEVANCE: Early oncology clinical trials have traditionally focused on defining the maximum tolerated dose for phase II development. Recent development of novel targeted agents demand a different approach that includes: 1) testing in a molecularly profiled population; 2) evaluation f intermediate biologic endpoints; and 3) determination of the optimal biologic dose for Phase II studies.
描述(由申请人提供):科学和生物技术的最新进展导致了大量快速发展的高通量分析的数据爆炸。虽然这些进展导致了几种难治性恶性肿瘤治疗的重大改进,但大多数晚期癌症仍然无法治愈。西南早期临床试验(SECT)联盟由得克萨斯大学MD安德森癌症中心和科罗拉多大学综合癌症中心组成,在战略和地理位置上,在广泛的患者人群中领导,合作和执行NCI实验治疗-临床试验网络的I期临床试验,包括在几个服务不足的地区。具体而言,我们建议:1.以有效和协作的方式研究新药或假设驱动的新型组合的安全性和临床活性。2.对患者(宿主组织)及其恶性肿瘤进行分子分析,以根据已识别的分子畸变(如适用)优化每例患者的潜在相关治疗选择。3.开发临床相关的药效学反应标志物。4.指导初级教师、学员和研究人员(如适用)领导、开展、分析和报告ET-CTN和其他临床试验。5.在ET-CTN内提供科学和行政领导,包括积极参与项目团队,研究设计和方案制定,网络组出版物的作者/合著者,以及参与科学,行政或特设委员会,以及参与NCI中央IRB和出席ET-CTN和IDSC会议。除了在临床试验累积、药代动力学和药效学评估方面的成熟能力外,SECT机构还拥有无与伦比的资源组合,包括获得大量具有广泛基因型肿瘤的患者群体、建立的生物储存库、最先进的临床基因组学能力和专家生物信息学。由三位经验丰富的具有互补技能的主要研究者领导,SECT联盟准备执行早期实验性治疗临床试验的新范式,目标是验证正确的途径,用正确的药物靶向这些途径,并在正确的患者中测试这些药物。
相关性:早期肿瘤临床试验传统上侧重于确定II期开发的最大耐受剂量。新型靶向药物的最新发展需要不同的方法,包括:1)在分子特征人群中进行测试; 2)评价中间生物学终点; 3)确定II期研究的最佳生物剂量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
S. Gail Eckhardt其他文献
Population pharmacokinetic model of PI-88, a heparanase inhibitor
- DOI:
10.1007/s00280-009-1080-z - 发表时间:
2009-07-25 - 期刊:
- 影响因子:2.300
- 作者:
Susan F. Hudachek;S. Gail Eckhardt;Barbara Hicks;Daniel L. Gustafson - 通讯作者:
Daniel L. Gustafson
A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma
Irofulven (MGI 114) 在 IV 期黑色素瘤患者中的 II 期研究
- DOI:
10.1023/a:1016261918256 - 发表时间:
2002 - 期刊:
- 影响因子:3.4
- 作者:
A. Scott Pierson;P. Gibbs;J. Richards;P. Russ;S. Gail Eckhardt;R. Gonzalez - 通讯作者:
R. Gonzalez
Sa1651: MICROBIAL IMMUNOMODULATION FOR ENHANCING IMMUNOTHERAPEUTIC EFFICACY IN A PATIENT-SPECIFIC COLORECTAL CANCER CHIP
- DOI:
10.1016/s0016-5085(22)61078-3 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Yong Cheol Shin;Alexander Wu;Soyoun Min;Dae Sung Kim;Woojung Shin;Linda A. Feagins;S. Gail Eckhardt;R.Y. Declan Fleming;Hyun Jung Kim - 通讯作者:
Hyun Jung Kim
Interrogating open issues in cancer precision medicine with patient-derived xenografts
用患者衍生的异种移植物来询问癌症精准医疗中的未解决问题
- DOI:
10.1038/nrc.2016.140 - 发表时间:
2017-01-20 - 期刊:
- 影响因子:66.800
- 作者:
Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali;Joaquín Arribas;Andrew V. Biankin;Alejandra Bruna;Eva Budinská;Carlos Caldas;David K. Chang;Robert B. Clarke;Hans Clevers;George Coukos;Virginie Dangles-Marie;S. Gail Eckhardt;Eva Gonzalez-Suarez;Els Hermans;Manuel Hidalgo;Monika A. Jarzabek;Steven de Jong;Jos Jonkers;Kristel Kemper;Luisa Lanfrancone;Gunhild Mari Mælandsmo;Elisabetta Marangoni;Jean-Christophe Marine;Enzo Medico;Jens Henrik Norum;Héctor G. Palmer;Daniel S. Peeper;Pier Giuseppe Pelicci;Alejandro Piris-Gimenez;Sergio Roman-Roman;Oscar M. Rueda;Joan Seoane;Violeta Serra;Laura Soucek;Dominique Vanhecke;Alberto Villanueva;Emilie Vinolo;Andrea Bertotti;Livio Trusolino - 通讯作者:
Livio Trusolino
S. Gail Eckhardt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('S. Gail Eckhardt', 18)}}的其他基金
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
- 批准号:
7022288 - 财政年份:2005
- 资助金额:
$ 44.37万 - 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
- 批准号:
7188524 - 财政年份:2005
- 资助金额:
$ 44.37万 - 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
- 批准号:
7356374 - 财政年份:2005
- 资助金额:
$ 44.37万 - 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
- 批准号:
7575675 - 财政年份:2005
- 资助金额:
$ 44.37万 - 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
- 批准号:
6871591 - 财政年份:2005
- 资助金额:
$ 44.37万 - 项目类别:
Overcoming Age-Dependent Barriers to Early Phase Trials
克服早期试验中年龄相关的障碍
- 批准号:
6666010 - 财政年份:2003
- 资助金额:
$ 44.37万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 44.37万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 44.37万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 44.37万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 44.37万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 44.37万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 44.37万 - 项目类别: